Intellectual property "rules should first serve inventors – not investors – to bring innovation to the marketplace, not fruitless litigation which destroys jobs and companies, and wastes a small company's limited resources," he told the committee...But that's not the case with intellectual property

intellectual property

Each country, which has identified itself as a player in biotech, is assigned a score in six fundamental categories: Intellectual Property (IP), Intensity, Enterprise Support, Education/Workforce, Foundations, and Policy and Stability – a classification that was added for the first time in the 2012 survey to explore a government's power to implement laws that impact on the development of their biotech industry

KingYork and Zendex are expected to contribute assets of RMB260 million, including cash, technology assets, intellectual property and land at KingYork's pharmaceutical business park in Tianjin where Kinnovata will establish its manufacturing facility

Each country, which has identified itself as a player in biotech, is assigned a score in six fundamental categories: Intellectual Property (IP), Intensity, Enterprise Support, Education/Workforce, Foundations, and Policy and Stability – a classification that was added for the first time in the 2012 survey to explore a government's power to implement laws that impact on the development of their biotech industry

Hours after reporting its first quarterly earnings as a commercial entity following FDA approval of Kynamro (mipomersen) in January and subsequent launch of the antisense drug, Isis Pharmaceuticals Inc. turned its attention to other candidates in its pipeline. The Carlsbad, Calif.-based company priced an underwritten public offering of 9 million shares of its common stock at $19 per share, seeking to raise $171 million from the offering, which is expected to close on or about May 14. Isis

The Biotechnology Industry Organization (BIO) expressed concern over weak intellectual property (IP) enforcement efforts in certain countries, following the Office of the U.S. Trade Representative's (USTR) release of its Special 301 Report

In general, Capital looks for an approved product with strong intellectual property and potential for growth in its therapeutic area

patent filing system from first-to-invent claims to a globally accepted first-to-file system, and intellectual property experts are still trying to see how it all will shake out and what it will mean for the timing of patent filings across the globe and the rules for public disclosure

patents, pending applications in all global markets and the ability to bypass most of the intellectual property issued around monoclonal antibodies

intellectual property and cell lines The acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancers and assumes rights to the existing agreement for GVAX Melanoma

patent filing system from first-to-invent claims to a globally accepted first-to-file system, and intellectual property experts are still trying to see how it all will shake out and what it will mean for the timing of patent filings across the globe and the rules for public disclosure

Instead, issues arise around business models, intellectual property and incentive structures, driving the need for new collaborative models

So said members of a panel on managing intellectual property in such territories during the BIO International Convention...You do have a window of time to think about it, but it's very important to think about those factors which are not specifically intellectual property-relate, but have massive impact on your ability to sell and develop worldwide," such as the situation in El Salvador

The 2012 called for the partners to build the Center for Advanced Cellular Therapies on the Penn campus in Philadelphia to focus on the discovery, development and manufacturing of adoptive T-cell immunotherapies through a joint research and development program led by investigators from Penn, Novartis and the Novartis Institutes, with the pharma gaining an exclusive worldwide license to CAR-based therapies developed through the collaboration. (See BioWorld Today, Sept. 20, 2012.) Intellectual

Founded in 2006 as a spin-off from the Vlaams Instituut voor Biotechnologie in Brussels and from Ghent University, the company has a broad intellectual property position

The company has licensed intellectual property from an Indian pharmaceutical firm, Chennai-based Orchid Chemicals & Pharmaceuticals Ltd., although further details are limited

The 2012 called for the partners to build the Center for Advanced Cellular Therapies on the Penn campus in Philadelphia to focus on the discovery, development and manufacturing of adoptive T-cell immunotherapies through a joint research and development program led by investigators from Penn, Novartis and the Novartis Institutes, with the pharma gaining an exclusive worldwide license to CAR-based therapies developed through the collaboration. (See BioWorld Today, Sept. 20, 2012.) Intellectual

Twelve instant partners sounds good, but there have been challenges, including internal staff resistance to the concept, data management hurdles and legal issues related to intellectual property (IP